Drug intelligence / Profile preview

GR1015

Development stage: Preclinical
Lead developer: GeneQuantum Biosciences
Modality: Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics

Overview

GR1015 is an antibody-drug conjugate (ADC) currently in development by GeneQuantum. It is engineered using the company's proprietary intelligent Ligase Dependent Conjugation (iLDC) technology, which is designed to produce highly homogeneous and stable ADCs through site-specific conjugation. While the specific molecular target and primary disease indications for GR1015 remain undisclosed by the developer, it is part of a broader pipeline of next-generation ADCs aimed at treating various cancers and immune-related conditions.

Beyond the preview

Go deeper on GR1015.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GR1015.

Explore the full profile